Investigating aggressive breast cancer in women of African descent
Official title: Full Project 1
Funded at University of California Riverside · NIH-10933470 · Data updated 2026-11-12
This study is looking at how certain aggressive breast cancers, especially in women of African descent, behave and resist treatment, with the goal of finding new ways to improve therapies by focusing on specific parts of a protein called MYC.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $209,343 |
| NIH project number | 5U54CA285114-02 |
| Project ID | NIH-10933470 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women of African descent diagnosed with luminal B breast cancer, particularly those with aggressive forms of the disease.
✕Less likely to help
Patients with other types of breast cancer or those not of African descent may not benefit from this specific research.
What this research studies
This research focuses on understanding the mechanisms behind aggressive luminal B breast cancers, particularly in women of African descent. It aims to identify specific acetylation sites on the MYC protein that contribute to cancer progression and resistance to therapies. By studying these molecular pathways, the research seeks to uncover new targets for drug development that could improve treatment outcomes for affected patients. The approach includes analyzing cancer cells and their signaling processes to better understand how they grow and resist current treatments.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve survival rates for women suffering from aggressive breast cancer.
How similar studies have gone: While there have been challenges in targeting MYC in cancer treatment, this research aims to explore novel mechanisms that have not been extensively tested, making it a potentially groundbreaking approach.
Where this research is happening
-
University of California Riverside
Riverside, United States Active
Researchers
- Principal investigator: Martinez, Ernest — University of California Riverside
- Study coordinator: Martinez, Ernest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.